The Thrombomodulin Analog Solulin Promotes Reperfusion and Reduces Infarct Volume in a Thrombotic Stroke Model

Overview

Journal J Thromb Haemost

Publisher Elsevier

Specialty Hematology

Date 2011 Jun 8

PMID 21645225

Citations 15

Authors

E J Su

M Geyer

M Wahl

K Mann

D Ginsburg

H Brohmann

K U Petersen

D A Lawrence

Affiliations

Soon will be listed here.

Abstract

Background: Currently there is no approved anticoagulant for treating acute stroke. This is largely because of concern for hemorrhagic complications, and suggests a critical need for safer anticoagulants. Solulin is a soluble analog of the endothelial cell receptor thrombomodulin, able to bind free thrombin and convert it to an activator of the anticoagulant, protein C.

Objective: Solulin was tested for its ability to inhibit middle cerebral artery occlusion (MCAO) induced by photothrombosis, and to restore MCA patency after establishment of stable occlusion.

Methods: Cerebral blood flow (CBF) was monitored by laser Doppler for 1.5 h after occlusion and again 72 h later.

Results: Solulin treatment 30 min before thrombosis resulted in an approximately 50% increase in time to form a stable occlusion. When administered 30 or 60 min after MCAO, Solulin significantly improved CBF within 90 min of treatment. In contrast, none of the vehicle-treated mice showed restoration of CBF in the first 90 min and only 17% did so by 72 h. Solulin treatment was associated with a significant reduction in infarct volume, and was well tolerated with no overt hemorrhage observed in any treatment group. Mechanistic studies in mice homozygous for the factor (F)V Leiden mutation, suggest that Solulin's efficacy derives primarily from the anticoagulant activity of the thrombin-Solulin complex and not from direct anti-inflammatory or neuroprotective effects of Solulin or activated protein C.

Conclusions: Our data indicate that Solulin is a safe and effective anticoagulant that is able to antagonize active thrombosis in acute ischemic stroke, and to reduce infarct volume.

Citing Articles

Cell-Specific Mechanisms in the Heart of COVID-19 Patients.

Tsai E, cihakova D, Tucker N Circ Res. 2023; 132(10):1290-1301.

PMID: 37167361 PMC: 10171292. DOI: 10.1161/CIRCRESAHA.123.321876.

Hypercoagulability Impairs Plaque Stability in Diabetes-Induced Atherosclerosis.

Ambreen S, Fatima S, Elwakiel A, Rana R, Singh K, Gupta A Nutrients. 2022; 14(10).

PMID: 35631132 PMC: 9143009. DOI: 10.3390/nu14101991.

Interleukin-1 receptor inhibition reduces stroke size in a murine model of sickle cell disease.

Venugopal J, Wang J, Mawri J, Guo C, Eitzman D Haematologica. 2020; 106(9):2469-2477.

PMID: 32817286 PMC: 8409048. DOI: 10.3324/haematol.2020.252395.

Thrombomodulin in disseminated intravascular coagulation and other critical conditions-a multi-faceted anticoagulant protein with therapeutic potential.

Ito T, Thachil J, Asakura H, Levy J, Iba T Crit Care. 2019; 23(1):280.

PMID: 31416465 PMC: 6694689. DOI: 10.1186/s13054-019-2552-0.

Protective effects of atorvastatin on cerebral vessel autoregulation in an experimental rabbit model of subarachnoid hemorrhage.

Chen J, Wu T, Yang L, Chen L, Zhu J, Li P Mol Med Rep. 2017; 17(1):1651-1659.

PMID: 29257200 PMC: 5780106. DOI: 10.3892/mmr.2017.8074.

References

Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana B, Mamoli A . Intravenous heparin started within the first 3 hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke. 2005; 36(11):2415-20. DOI: 10.1161/01.STR.0000185730.50480.e7. View

Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K . Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost. 2010; 105(2):302-12. DOI: 10.1160/TH10-05-0287. View

Mosnier L, Meijers J, Bouma B . Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost. 2001; 85(1):5-11. View

Su E, Fredriksson L, Geyer M, Folestad E, Cale J, Andrae J . Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med. 2008; 14(7):731-7. PMC: 2811427. DOI: 10.1038/nm1787. View

Stoll G, Kleinschnitz C, Nieswandt B . Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood. 2008; 112(9):3555-62. DOI: 10.1182/blood-2008-04-144758. View

Bajzar L, Morser J, Nesheim M . TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem. 1996; 271(28):16603-8. DOI: 10.1074/jbc.271.28.16603. View

Yepes M, Sandkvist M, Wong M, Coleman T, Smith E, Cohan S . Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood. 2000; 96(2):569-76. View

Sandercock P, Counsell C, Gubitz G, Tseng M . Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2008; (3):CD000029. DOI: 10.1002/14651858.CD000029.pub2. View

Zhao B, Ikeda Y, Ihara H, Urano T, Fan W, Mikawa S . Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood. 2003; 103(7):2610-6. DOI: 10.1182/blood-2003-03-0835. View

10.

Wang W, Nagashima M, Schneider M, Morser J, Nesheim M . Elements of the primary structure of thrombomodulin required for efficient thrombin-activable fibrinolysis inhibitor activation. J Biol Chem. 2000; 275(30):22942-7. DOI: 10.1074/jbc.M001760200. View

11.

Lane D, Philippou H, Huntington J . Directing thrombin. Blood. 2005; 106(8):2605-12. DOI: 10.1182/blood-2005-04-1710. View

12.

Wong K, Chen C, Ng P, Tsoi T, Li H, Fong W . Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study. Lancet Neurol. 2007; 6(5):407-13. PMC: 7185651. DOI: 10.1016/S1474-4422(07)70079-0. View

13.

Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis T . Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke. 2008; 40(5):1864-9. PMC: 2691176. DOI: 10.1161/STROKEAHA.108.536680. View

14.

Parker A, Mundada L, Schmaier A, Fay W . Factor VLeiden inhibits fibrinolysis in vivo. Circulation. 2004; 110(23):3594-8. DOI: 10.1161/01.CIR.0000148781.87906.C0. View

15.

Fumagalli R, Mignini M . The safety profile of drotrecogin alfa (activated). Crit Care. 2008; 11 Suppl 5:S6. PMC: 2230610. DOI: 10.1186/cc6157. View

16.

Green A . Pharmacological approaches to acute ischaemic stroke: reperfusion certainly, neuroprotection possibly. Br J Pharmacol. 2007; 153 Suppl 1:S325-38. PMC: 2268079. DOI: 10.1038/sj.bjp.0707594. View

17.

Bajzar L, Kalafatis M, Simioni P, Tracy P . An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLeiden. J Biol Chem. 1996; 271(38):22949-52. DOI: 10.1074/jbc.271.38.22949. View

18.

Cui J, Eitzman D, Westrick R, Christie P, Xu Z, Yang A . Spontaneous thrombosis in mice carrying the factor V Leiden mutation. Blood. 2000; 96(13):4222-6. View

19.

Esmon C, Owen W . Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci U S A. 1981; 78(4):2249-52. PMC: 319322. DOI: 10.1073/pnas.78.4.2249. View

20.

Lloyd-Jones D, Adams R, Brown T, Carnethon M, Dai S, de Simone G . Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2009; 121(7):e46-e215. DOI: 10.1161/CIRCULATIONAHA.109.192667. View